RxDoctor Payments DataLook up a doctor →

Jay Mahajan, DO

Neurology · Las Vegas, NVNPI 1053632992

Payments from drug & device makers

$103,860in general payments, 2019–2025

Across 821 payments — averaging $126.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$71K
  • UCB SA$17K
  • AbbVie$4K
  • Neurocrine Biosciences, Inc.$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$897
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC2$70,748
UCB SA3$16,639
AbbVie(2 entities)192$4,046
Neurocrine Biosciences, Inc.43$1,455
Novartis90$1,410
Teva Pharmaceuticals USA, Inc.48$897
Pfizer48$812
UCB, Inc.33$764
AstraZeneca(2 entities)37$700
Genentech USA, Inc.38$559
Amgen(2 entities)28$503
Lundbeck LLC28$420
Abbott6$420
Argenx US, Inc.22$346
EMD Serono, Inc.13$313
SK Life Science, Inc.11$223
Takeda Pharmaceuticals U.S.A., Inc.9$222
Biohaven Pharmaceutical Holding Company Ltd.13$213
CSL Behring10$206
Sanofi9$198
Sunovion Pharmaceuticals Inc.12$177
MDD US Operations, LLC9$170
Bristol Myers Squibb4$135
ANI Pharmaceuticals, Inc.6$128
Nevro Corp.1$127
Otsuka America Pharmaceutical, Inc.5$117
Biogen6$114
Acadia Pharmaceuticals Inc5$108
Octapharma USA, Inc.7$106
Livanova USA, Inc.3$104
Boston Scientific1$100
Mallinckrodt Hospital Products Inc.5$98
Catalyst Pharmaceuticals, Inc.5$85
Mallinckrodt Enterprises LLC4$83
Ipsen Biopharmaceuticals, Inc4$83
Acorda Therapeutics, Inc6$82
Biohaven Pharmaceuticals, Inc.3$74
Impel Pharmaceuticals Inc.3$60
Johnson & Johnson(2 entities)3$55
Eisai Inc.3$54
Sumitomo Pharma America, Inc.3$52
Tanabe Pharma America, Inc.3$51
Grifols USA, LLC3$49
Avanir Pharmaceuticals, Inc.3$48
Aucta Pharmaceuticals, Inc.4$44
Neuropace, Inc.1$41
Zyla Life Sciences, Inc.3$38
Upsher-smith Laboratories LLC2$36
Merz Pharmaceuticals, LLC1$31
Jazz Pharmaceuticals Inc.1$30
Alnylam Pharmaceuticals Inc.1$25
Assertio Therapeutics, Inc.2$22
Philips North America LLC1$20
Merz North America, Inc.1$19
Sanofi-aventis U.S. LLC1$19
Aquestive Therapeutics, Inc.1$18
Lilly USA, LLC1$18
NS Pharma, Inc.1$18
Neurelis, Inc.1$17
Avion Pharmaceuticals1$16

How this compares

$103,860 in reported general payments places this provider in the 85th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada →

Medicare billing

Part B allowed, 2024
$2,544,661
Medicare patients
1,311
Services billed
37,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →